HAYLEY FOLSE: Open Payments
NPI 1639694623 · RACELAND, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,991 in 134 payments from 13 companies in 2025. Trend: 2023 $2,091 · 2024 $2,072 · 2025 $1,991
Food & beverage: $1,991
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 18 | $250 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 15 | $224 |
| E.R. Squibb & Sons, L.L.C. | 15 | $199 |
| Vanda Pharmaceuticals Inc. | 9 | $174 |
| Lundbeck LLC | 14 | $172 |
| ABBVIE INC. | 12 | $167 |
| Teva Pharmaceuticals USA, Inc. | 11 | $166 |
| Janssen Pharmaceuticals, Inc | 9 | $151 |
| Neurocrine BioSciences, Inc. | 10 | $150 |
| Otsuka America Pharmaceutical, Inc. | 9 | $138 |
Products named: ARISTADA, CAPLYTA, REXULTI, COBENFY, FANAPT, VRAYLAR, INGREZZA, INVEGA.
Industry payments across LA — which companies pay providers there.
